"<h2 class="""" data-start=""60"" data-end=""75"">Introduction</h2>
<p class="""" data-start=""77"" data-end=""234""><span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]"">Glucagon is a critical hormone in glucose metabolism, primarily used in medical settings to treat severe hypoglycemia.</span> <span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]"">The global glucagon market has experienced significant growth, driven by the increasing prevalence of diabetes and advancements in drug delivery systems.</span> <span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]"">This article provides a comprehensive overview of leading companies in the glucagon market, focusing on Novo Nordisk, Eli Lilly, and Fresenius Kabi, detailing their headquarters, revenue figures, and growth trajectories.</span></p>
<h2 class="""" data-start=""236"" data-end=""254"">1. Novo Nordisk</h2>
<p class="""" data-start=""256"" data-end=""355""><strong data-start=""256"" data-end=""273"">Headquarters:</strong> <span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]"">Bagsv&aelig;rd, Denmark</span></p>
<p class="""" data-start=""357"" data-end=""568""><strong data-start=""357"" data-end=""370"">Overview:</strong> <span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]"">Novo Nordisk is a global healthcare company with a strong legacy in diabetes care.</span> <span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]"">The company offers GlucaGen HypoKit, a glucagon emergency kit designed for the treatment of severe hypoglycemia.</span> <span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]"">Novo Nordisk continues to innovate in the glucagon sector, focusing on developing more efficient and user-friendly products.</span></p>
<p class="""" data-start=""357"" data-end=""568""><span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]""><strong>To Learn more about this Report, Request Free Sample PDF @&nbsp;<a href=""https://www.globalmarketstatistics.com/market-reports/glucagon-market-12407"">https://www.globalmarketstatistics.com/market-reports/glucagon-market-12407</a></strong></span></p>
<p class="""" data-start=""570"" data-end=""720""><strong data-start=""570"" data-end=""594"">Recent Developments:</strong> <span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]"">In September 2022, Novo Nordisk entered a collaborative agreement with Zealand Pharma to in-license Zegalogue, a next-generation glucagon for treating severe hypoglycemia.</span> </p>
<h2 class="""" data-start=""722"" data-end=""749"">2. Eli Lilly and Company</h2>
<p class="""" data-start=""751"" data-end=""854""><strong data-start=""751"" data-end=""768"">Headquarters:</strong> <span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]"">Indianapolis, Indiana, USA</span></p>
<p class="""" data-start=""856"" data-end=""1035""><strong data-start=""856"" data-end=""869"">Overview:</strong> <span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]"">Eli Lilly has been a significant player in the glucagon market, known for its Glucagon Emergency Kit.</span> <span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]"">The company also developed Baqsimi, the first nasal glucagon powder approved for treating severe hypoglycemia, simplifying administration during emergencies.</span> </p>
<p class="""" data-start=""1037"" data-end=""1187""><strong data-start=""1037"" data-end=""1061"">Recent Developments:</strong> <span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]"">In June 2023, Eli Lilly disclosed phase 2 findings for orforglipron, its inaugural nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist under investigation for chronic weight management in subjects dealing with obesity or overweight.</span> </p>
<h2 class="""" data-start=""1189"" data-end=""1209"">3. Fresenius Kabi</h2>
<p class="""" data-start=""1211"" data-end=""1314""><strong data-start=""1211"" data-end=""1228"">Headquarters:</strong> <span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]"">Bad Homburg, Germany</span></p>
<p class="""" data-start=""1316"" data-end=""1535""><strong data-start=""1316"" data-end=""1329"">Overview:</strong> <span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]"">Fresenius Kabi is a global healthcare company specializing in lifesaving medicines and technologies.</span> <span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]"">The company introduced its Glucagon Emergency Kit in the U.S. to treat severe hypoglycemia in diabetic patients.</span> <span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]"">The kit includes 1 mg of Glucagon for Injection and a prefilled syringe with sterile water, designed for easy and quick administration during emergencies.</span></p>
<p class="""" data-start=""1537"" data-end=""1687""><strong data-start=""1537"" data-end=""1561"">Recent Developments:</strong> <span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]"">Fresenius Kabi has focused on enhancing the accessibility and affordability of its glucagon products, including offering co-pay assistance programs to ensure broader patient access.</span>&nbsp;</p>
<h2 class="""" data-start=""1689"" data-end=""1707"">Market Overview</h2>
<p class="""" data-start=""1709"" data-end=""1874""><span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]"">The global glucagon market has been experiencing steady growth, driven by the increasing prevalence of diabetes and advancements in drug delivery systems.</span> <span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]"">According to market research, the global glucagon market size was valued at USD 278.5 million in 2022 and is projected to grow from USD 297.8 million in 2023 to USD 470.8 million by 2030, exhibiting a compound annual growth rate (CAGR) of 6.8% during the forecast period.</span></p>
<p class="""" data-start=""1709"" data-end=""1874""><span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]""><strong>To Learn more about this Report, Request Free Sample PDF @&nbsp;<a href=""https://www.globalmarketstatistics.com/market-reports/glucagon-market-12407"">https://www.globalmarketstatistics.com/market-reports/glucagon-market-12407</a></strong></span></p>
<h2 class="""" data-start=""1876"" data-end=""1889"">Conclusion</h2>
<p class="""" data-start=""1891"" data-end=""2016""><span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]"">The glucagon market is characterized by the presence of key players like Novo Nordisk, Eli Lilly, and Fresenius Kabi, each contributing significantly through innovative products and strategic initiatives.</span> <span class=""relative -mx-px my-[-0.2rem] rounded-sm px-px py-[0.2rem]"">As the market continues to expand, these companies are poised to play pivotal roles in addressing the growing demand for effective hypoglycemia treatments.</span></p>"
